Novel prognostic biomarkers in colorectal cancer

Digestive Diseases

Volumn 30, Issue 3, 2012, Pages 296-303

  Malesci, Alberto ^a,b   Laghi, Luigi ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarkers; Colorectal cancer; TNM staging

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL;

AMINO ACID SUBSTITUTION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; CHROMOSOME LOSS; COLORECTAL CANCER; CPG ISLAND; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA METHYLATION; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; MICROSATELLITE INSTABILITY; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENES, NEOPLASM; HUMANS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862886158     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000336996     Document Type: Review

References (37)

1. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425. (Pubitemid 39429665)
2. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). Nat Clin Pract 2005; 2: 416-422. (Pubitemid 43115010)
3. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
4. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170. (Pubitemid 26358996)
5. Araujo SE, Bernardo WM, Habr-Gama A, Kiss DR, Cecconello I: DNA ploidy status and prognosis in colorectal cancer: A metaanalysis of published data. Dis Colon Rectum 2007; 50: 1800-1810. (Pubitemid 350077095)
6. Kim MY, Yim SH, Kwon MS, et al: Recurrent genomic alterations with impact on survival in colorectal cancer identified by genomewide array comparative genomic hybridization. Gastroenterology 2006; 131: 1913-1924.
7. Sayagues JM, Abad Mdel M, Melchor HB, et al: Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol 2010; 221: 308-319.
8. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221. (Pubitemid 24226678)
9. Laghi L, Bianchi P, Malesci A: Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 2008; 27: 6313-6321.
10. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618. (Pubitemid 46224239)
11. Malesci A, Laghi L, Bianchi P, et al: Reduced likelihood of metastases in patients with microsatellite- unstable colorectal cancer. Clin Cancer Res 2007; 13: 3831-3839. (Pubitemid 47037588)
12. Kim GP, Colangelo LH, Paik S, et al: Predictive value of microsatellite instability-high remains controversial. J Clin Oncol 2007; 25: 4857, author reply 8. (Pubitemid 350086499)
13. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
14. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875.
15. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
16. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ: Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003; 21: 3729-3736. (Pubitemid 46606226)
17. Weisenberger DJ, Siegmund KD, Campan M, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793. (Pubitemid 43980599)
18. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.
19. English DR, Young JP, Simpson JA, et al: Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008; 17: 1774-1780.
20. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR: Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114: 1188-1195. (Pubitemid 28243904)
21. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206. (Pubitemid 32319494)
22. Ogino S, Nosho K, Irahara N, et al: Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009; 27: 4591-4598.
23. Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005; 92: 434-444. (Pubitemid 40395523)
24. Iacopetta B, Russo A, Bazan V, et al: Functional categories of TP53 mutation in colorectal cancer: Results of an international collaborative study. Ann Oncol 2006; 17: 842-847.
25. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-696. (Pubitemid 32929467)
26. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
27. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
28. Pages F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666. (Pubitemid 41817714)
29. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964. (Pubitemid 44498003)
30. Laghi L, Bianchi P, Miranda E, et al: CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol 2009; 10: 877-884.
31. Ogino S, Galon J, Fuchs CS, Dranoff G: Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8: 711-719.
32. Pages F, Kirilovsky A, Mlecnik B, et al: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951.
33. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ: Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-1279.
34. Salama P, Phillips M, Grieu F, et al: Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
35. Nosho K, Baba Y, Tanaka N, et al: Tumourinfiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: Cohort study and literature review. J Pathol 2010; 222: 350-366.
36. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13: 1472-1479. (Pubitemid 46450437)
37. Kloor M, Becker C, Benner A, et al: Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005; 65: 6418-6424. (Pubitemid 40994430)